Affiliation:
1. School of Life Sciences, College of Natural Sciences, Kyungpook National University, Daegu 41566, Korea
2. Department of Chemical Engineering, College of Engineering, Dhofar University, Salalah, Oman
3. Department of Clinical Pharmacy, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia
Abstract
Background:
Natural phytochemicals and their derivatives have been used in medicine since prehistoric
times. Natural phytochemicals have potential uses against various disorders, including cancers. However,
due to low bioavailability, their success in clinical trials has not been reproduced. Nanotechnology has played a
vital role in providing new directions for diagnosis, prevention, and treatment of different disorders, and of cancer
in particular. Nanotechnology has demonstrated the capability to deliver conventional natural products with poor
solubility or a short half-life to target specific sites in the body and regulate the release of drugs. Among the natural
products, the phytoalexin resveratrol has demonstrated therapeutic effects, including antioxidant, antiinflammatory,
and anti-proliferative effects, as well as the potential to inhibit the initiation and promotion of
cancer. However, low water solubility and extensive first-pass metabolism lead to poor bioavailability of resveratrol,
hindering its potential. Conventional dosage forms of resveratrol, such as tablets, capsules, dry powder, and
injections, have met with limited success. Nanoformulations are now being investigated to improve the pharmacokinetic
characteristics, as well as to enhance the bioavailability and targetability of resveratrol.
Objectives:
This review details the therapeutic effectiveness, mode of action, and pharmacokinetic limitations of
resveratrol, as well as discusses the successes and challenges of resveratrol nanoformulations. Modern nanotechnology
techniques to enhance the encapsulation of resveratrol within nanoparticles and thereby enhance its therapeutic
effects are emphasized.
Conclusion:
To date, no resveratrol-based nanosystems are in clinical use, and this review would provide a new
direction for further investigations on innovative nanodevices that could consolidate the anticancer potential of
resveratrol.
Funder
National Research Foundation of Korea
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献